Loading…
Tatva Chintan Pharma Chem (TATVA)₹1,668+2.70%Specialty Chemicals
At the end of the Sep 2026 quarter, Tatva Chintan Pharma Chem's shareholders were: promoters 72.08%, FIIs 4.35%, DIIs 3.23%, public 20.34%. Promoter holding is unchanged on the quarter. FII holding is up 0.97 percentage points from 3.38% a year earlier. 0.00% of promoter shares were pledged. It had 62,895 shareholders.
As of · Company filings (shareholding pattern)
| Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 72.08% | 72.08% | 72.08% | 72.08% | 72.08% | 72.08% | 72.08% | 72.08% | 72.08% | 72.08% | 72.08% | 72.08% |
| FIIs | 4.18% | 3.63% | 3.35% | 3.31% | 3.34% | 3.28% | 3.24% | 3.38% | 4.14% | 3.78% | 3.90% | 4.35% |
| DIIs | 13.10% | 12.88% | 10.68% | 6.87% | 6.38% | 5.49% | 5.14% | 3.89% | 3.34% | 3.01% | 3.13% | 3.23% |
| Public | 10.64% | 11.41% | 13.89% | 17.74% | 18.20% | 19.15% | 19.54% | 20.65% | 20.44% | 21.13% | 20.89% | 20.34% |
| Promoter shares pledged | — | — | — | — | — | — | — | — | — | — | — | 0.00% |
| Number of shareholders | 74,528 | 73,738 | 73,920 | 79,632 | 79,018 | 78,402 | 76,801 | 73,339 | 68,665 | 66,850 | 64,928 | 62,895 |
| Holder | Category | Sep 2026 | Change (pp) |
|---|---|---|---|
| Shekhar Rasiklal Somani | Promoter | 23.03% | 0.00 |
| Chintan Nitinkumar Shah | Promoter | 20.93% | 0.00 |
| Ajay Mansukhlal Patel | Promoter | 20.11% | 0.00 |
| Priti Ajay Patel | Promoter | 3.83% | 0.00 |
| Goldman Sachs Funds - Goldman Sachs India Equity Portfolio | FII | 2.57% | 0.00 |
| Nippon Life India Trustee Ltd-A/C Nippon India Elss Tax Saver Fund | DII | 2.22% | 0.00 |
| Mukul Mahavir Agrawal | Public | 2.15% | 0.00 |
| Chintan N Shah (HUF) | Promoter | 1.92% | 0.00 |
| Shital Chintan Shah | Promoter | 0.99% | 0.00 |
| Kajalben Shekharkumar Somani | Promoter | 0.93% | 0.00 |
| Darshana Nitinkumar Shah | Promoter | 0.17% | 0.00 |
Promoters held 72.08% of Tatva Chintan Pharma Chem at the end of the Sep 2026 quarter, the same as a year earlier.
In the Sep 2026 quarter, foreign institutional investors (FIIs) held 4.35% (up 0.45 percentage points from 3.90% a quarter earlier) and domestic institutions (DIIs) held 3.23% (up 0.10 percentage points from 3.13% a quarter earlier).
No. The Sep 2026 filing shows no pledged promoter shares.
Tatva Chintan Pharma Chem had 62,895 shareholders at the end of the Sep 2026 quarter, against 73,339 a year earlier.
Goldman Sachs Funds - Goldman Sachs India Equity Portfolio (FII) held 2.57% at the end of the Sep 2026 quarter, the largest named holding outside the promoter group.